Clinical Trial Update: Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients [Phase 1]

View source ↗

Summary

A Phase 1 single- and multiple-dose study assessing the safety and pharmacokinetics of SAR228810 in Alzheimer's disease patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• SAR228810

Snippet

Sponsor: Sanofi | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED